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Abstract: Therapeutic targeting of PI3K-Akt-mTOR is considered a possible strategy in human acute
myeloid leukaemia (AML); the most important rationale being the proapoptotic and antiproliferative
effects of direct PI3K/mTOR inhibition observed in experimental studies of human AML cells.
However, AML is a heterogeneous disease and these effects caused by direct pathway inhibition
in the leukemic cells are observed only for a subset of patients. Furthermore, the final effect of
PI3K-Akt-mTOR inhibition is modulated by indirect effects, i.e., treatment effects on AML-supporting
non-leukemic bone marrow cells. In this article we focus on the effects of this treatment on
mesenchymal stem cells (MSCs) and monocytes/macrophages; both these cell types are parts of the
haematopoietic stem cell niches in the bone marrow. MSCs have unique membrane molecule and
constitutive cytokine release profiles, and mediate their support through bidirectional crosstalk
involving both cell-cell contact and the local cytokine network. It is not known how various
forms of PI3K-Akt-mTOR targeting alter the molecular mechanisms of this crosstalk. The effect
on monocytes/macrophages is also difficult to predict and depends on the targeted molecule. Thus,
further development of PI3K-Akt-mTOR targeting into a clinical strategy requires detailed molecular
studies in well-characterized experimental models combined with careful clinical studies, to identify
patient subsets that are likely to respond to this treatment.
Keywords: acute myeloid leukaemia; mesenchymal stem cells; therapy; stem cell niche; PI3K-Akt-mTOR;
monocytes; membrane molecules; cytokine release
1. Introduction
The intracellular signalling mediators phosphoinositide 3-kinase (PI3K), Akt (protein kinase
B/PKB) and mammalian target of rapamycin (mTOR) form a signalling network rather than a signalling
pathway, and, as will be discussed later, targeted therapy directed against members of this network
is now considered as a possible strategy in the treatment of human acute myeloid leukaemia (AML).
However, this network is not only important in the leukemic cells but also for various non-leukemic
cells in the bone marrow (BM). Thus, PI3K-Akt-mTOR targeting will not only affect leukemic cells but
also their neighbouring leukaemia-supporting stromal cells [1,2]. In the present review we therefore
discuss the role of the PI3K-Akt-mTOR pathway and the complexity of targeting this network in AML;
we focus especially on the leukaemia-supporting mesenchymal stem cells (MSCs) that are regarded
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as important parts of the stem cell niches in the BM but we also describe effects of this therapeutic
strategy on the AML cells as well the effects on monocytes because these immunocompetent cells also
contribute to the formation of stem cell niches [3].
2. PI3K-Akt-mTOR Signalling
PI3K-Akt-mTOR signalling regulates many key functions in a wide range of cells. The members
of this pathway control the expression of proteins that regulate both apoptosis and cell cycle
progression/proliferation [4,5], they are important for cell trafficking/mobility and thereby become
important for angiogenesis [6], they are important regulators of cellular metabolism [7], and the furthest
downstream members of the pathway control protein synthesis and thereby cellular differentiation [5].
An overview of the pathway and how dysregulation of it is involved in many human cancers is given
below (see also Figure 1), and the pharmacological targeting of various members/regulators of the
pathway is discussed in Section 2.4.
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Figure 1. The PI3K-Akt-mTOR pathway. Signalling through this pathway can be initiated through
growth factor ligation of specific receptors. PI3K is then activated which leads to formation of PIP3
that activates/phosphorylates Akt. PTEN has PI3K-opposing effect on the equilibrium between PIP2
and PIP3, thereby inhibiting activation of Akt and its downstream partners. Final activation of Akt
is mediated by PDK-1 and mTORC2. mTORC1 is activated by Akt, and is inhibited by rapamycin,
AMPK and the TSC1/TSC2 complex. Akt is a negative regulator of the latter. Green colour indicates
inhibitory activity, red colour indicates activation of signalling through the pathway.
2.1. PI3K
The recruitment of PI3K to the plasma membrane is stimulated by growth factors as well as
several other cytokines and attachment of the cells to the extracellular matrix [8]. PI3K is activated
through auto-phosphorylation [4]. The most important substrate of the kinase is phosphatidylinositol
4,5-bisphosphate (PtdIns(4,5)P2 or simply PIP2); this mediator is further phosphorylated to
phosphatidylin sitol 3,4,5-trisphosp ate (PtdIns(3,4,5)P3 or PIP3) [7] which activates Akt and thereby
regulates cell cycle progression, apoptosis and the cel lar response to insulin [8]. The phosphatase and
tensin homolog (PTEN) catalyses the reverse reaction, i.e., dephosphorylation of PIP3 back to PIP2 [9].
PIP3 provides an anchor for several proteins, including Akt and 3-phosphoinositide-dependent protein
kinase 1 (PDK-1) domain [7].
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2.2. Akt (Protein Kinase B)
Akt is one of the key molecules downstream to PI3K. Upon binding to PI3K through its N-terminal
pleckstrin homology domain [8], Akt gets activated by phosphorylation at the two sites T308 and S473
that can be phosphorylated independently of each other [10]. Single phosphorylation results in lower
activity of Akt [11], but S473 phosphorylation seems to have more influence on substrate specificity
than absolute protein activity [12,13]. T308 is phosphorylated by PDK-1, whereas the mammalian
target of rapamycin complex 2 (mTORC2) carries out the phosphorylation of S473 [7]. Once activated,
Akt translocates from the membrane to the cytosol and the nucleus where it phosphorylates its
targets at specific serine and threonine residues [4]. Akt has a substrate specificity towards the
motif RxRxxS/Txbulk, where the amino acids at positions four and five preferentially are small and
xbulk is an aromatic amino acid [14]. Approximately 9500 human proteins contain such a motif,
but Akt also has a protein docking site so that potential substrates not necessarily have to contain
this motif [8]. Akt regulates cellular metabolism, growth and survival of many different cell types,
including endothelial cells (ECs) responsible for angiogenesis [7]. Induction of such functional effects
probably involves modulation of a wide range of proteins, including inhibition of cell cycle arrest by
phosphorylating p21 and increased translation rate of cell cycle regulator cyclin D [8].
2.3. mTOR
One important substrate of Akt is mTOR, a large protein with a C-terminal serine/threonine
PI3K-related kinase domain [2,9,15]. mTOR is a part of the two protein complexes mTORC1 and
mTORC2. The former is activated by Akt and acts also as inhibitor of Akt through negative
feedback [7], whereas the latter complex phosphorylates Akt at S473 to alter its substrate specificity [15].
The activation of mTORC1 is controlled by the tumour suppressor tuberous sclerosis complexes 1
and 2 (forming the TSC1/TSC2 dimer) that promote the formation of the mTOR complex only upon
inhibition by Akt [16].
Binding of rapamycin to FKBP-12 inhibits the activity of the mTORC1 complex [9] that consists of
mTOR, regulatory-associated protein of mTOR (raptor) and mammalian lethal with SEC13 protein 8
(mLST8, also called Gβ-like protein/GβL) [13]. Raptor and mLST8 are positive regulators of mTORC1;
the former protein binds to S6 kinase 1 (S6K1) and 4E-binding protein 1 (4E-BP1) that are the two most
important substrates of the complex, whereas mLST8 stabilizes the association between mTOR and
raptor and activates mTOR in the presence of nutrients [9]. On the other hand, the mTORC2 complex
is not inhibited by rapamycin [7], and contains mTOR, rapamycin-insensitive companion of mTOR
(rictor), mLST8 and stress-activated protein kinase-interacting protein 1 (Sin1) [13]. Rictor, mLST8 and
Sin1 are all essential for maintenance and function of the complex [12,17], and Sin1 seems to be the key
regulator of its nutrient-independent activation of Akt [13].
mTOR is regulated by insulin and insulin growth factors (IGFs) [13], nutrients (especially amino
acids) [18], available ATP [9] and various forms of stress (e.g., hypoxia and DNA damage) [19].
The main task of mTORC1 is to mediate protein synthesis via activation of S6K1 that enhances mRNA
translation, and to inhibit 4E-BP1, thus facilitating mRNA binding to the small ribosomal subunit [4].
mTORC1 is also important for ribosome biogenesis and recruitment [9], degradation of cytoplasmic
contents upon nutrient starvation (so-called macroautophagy) and the control of trafficking, uptake and
metabolism of nutrients such as glucose, amino acids, lipoproteins and iron [18,20]. The signal
transducer and activator of transcription 3 (Stat3) is also a substrate of mTORC1 [21]. The function of
mTORC2 is activation of Akt and in addition organization of the actin cytoskeleton [15] and regulation
of cell survival and metabolism [22].
2.4. Pharmacological Targeting of the PI3K-Akt-mTOR Pathway
It can be seen from Figure 1 that the PI3K-Akt-mTOR pathway is part of a signalling network,
and the activity is modified by several regulators that target different components of the main signalling
Molecules 2016, 21, 1512 4 of 32
pathway. As exemplified in Table 1 [23–27], several different inhibitors have been developed. Some of
these mediators inhibit the signalling through inhibition of single signalling mediators in the pathway
(i.e., PI3K, Akt or mTOR), whereas others have indirect effects through activation of inhibitory pathway
regulators (i.e., PTEN of AMPK). Several combined inhibitors have also been developed. One would
expect these diverse mediators to differ in their final effects on pathway signalling and the balance
between activation of the various downstream mediators.
Table 1. Pharmacological targeting of the PI3K-Akt-mTOR—an overview of various pharmacological
agents directed against different mediators/regulators of the pathway [23–27].
Direct Inhibition of the PI3K-Akt-mTOR Pathway Members
PI3K inhibitors
Pan-PI3K inhibitors: buparlisib, pilaralisib, pictilisib
Isoform-specific inhibitors: alpelisib, tazelisib, CAL-101, GDC-0941




MK-2206, uprosertib, ipatasertib, AZD5363
mTORC1 inhibitors
Sirolimus, everolimus, temsirolimus, ridaforolimus
Dual mTORC1/2 inhibitors
LNK128, AZD8055, MLN0138, CC-223
Indirect Inhibition—Activation of Pathway Inhibitors
AMPK agonists: metformin, A-769662GSK621
PTEN activation: L-sercurinine
The mTOR inhibitors differ with regard to their specificity (i.e., inhibition of mTORC1 alone or
dual mTOR inhibition). Additional references together with a more detailed discussion with regard to
characterization of the specificity for new mTOR inhibitors are given in previous articles [23,26].
To conclude, targeting of the PI3K-Akt-mTOR pathway is now regarded as a possible therapeutic
strategy in many human cancers [28]. Several agents targeting members of this pathway or their
regulators have been developed, and as described in detail by Bertacchini et al. [24] many of them are
now in clinical trials. Several of these new agents are tried in AML therapy (e.g., AZD-53, CAL-101,
MK2206, NVP-BEZ235, OSI-027, PP242).
3. Direct Effects of PI3K-Akt-mTOR Inhibition on AML Cells: Patient Heterogeneity and
Resistance to Treatment
3.1. Dysregulation of PI3K-Akt-mTOR in Human Malignancies—General Comments
Dysregulation of the PI3K-Akt-mTOR pathway, resulting in growth enhancement, resistance
to apoptosis and altered metabolism [29], plays a crucial role in the development of various
cancers and mutations of proteins belonging to this pathway are, second to mutations in p53,
the most frequent alterations in human malignancies [30]. Akt is a central node in tumourigenesis
and although the protein itself is rarely mutated [10], it is hyperactivated in many cancers [5]
leading to increased cell metabolism, proliferation and survival [9]. Akt overactivation has also been
correlated with poor prognosis [5], drug resistance [7] and tumour angiogenesis [8]. Constitutive
Akt overexpression/activation is in most cases either a result of a mutation in a tumour suppressor
(e.g., PTEN) [5,31] or a potential oncogene (e.g., the p110α regulatory domain of PI3K) [32]. However,
single drug treatment of cancers with PI3K-Akt-mTOR dysregulation has proven to be difficult;
treatment with rapamycin may knock out mTORC1 completely, but it might also cause enhanced
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growth factor-initiated activation of PI3K and Akt (e.g., by IGF-1) leading to signalling through other
downstream targets than mTORC1, for instance members of the forkhead box (FOX) transcription factor
family [29]. Furthermore, the PI3K-Akt-mTOR pathway is intertwined with the mitogen-activated
protein kinases-extracellular signal-regulated kinases (MAPK-ERK) pathway, and inhibition of Akt
or mTORC1 may therefore lead to MAPK activation and thereby drug resistance [33–35]. However,
combining PI3K and mTORC1 inhibition may have synergistic effects [29]; the same seems to be true
for combined blockage of PI3K-Akt-mTOR and MAPK-ERK [35].
3.2. PI3K-Akt-mTOR Targeting in Human AML
As described and discussed in detail in several recent excellent reviews, inhibition of PI3K-Akt-mTOR
is now considered as a therapeutic strategy in AML [1,23,25,36–39]. Several of the aspects for cancer
in general (described above) are also relevant for AML. The previous studies of PI3K-Akt-mTOR
inhibition as a therapeutic approach in AML have shown the following results:
• 50%–80% of AML patients display Akt that is phosphorylated at T308, S473 or both. This upregulation
has been detected not only in bulk AML cells but also in the more immature leukemic stem
cells [36,37]. Several studies suggest that both overall and disease-free survival is shorter in
patients with PI3K-Akt-mTOR pathway upregulation [36]. In contrast, constitutive activation of
the upstream PI3K may represent a favourable prognostic parameter [40].
• The causes for activation of PI3K-Akt-mTOR signalling can be mutations in the FMS-like
tyrosine kinase 3 (Flt3), proto-oncogene c-Kit (CD117) or K-Ras genes, overexpression of
PI3K or PDK-1, low levels of protein phosphatase 2 (PP2A), autocrine or paracrine release
of growth factors (e.g., IGF-1, platelet-derived growth factor/PDGF or the chemokine CXCL12),
stromal/fibronectin-induced upregulation of integrin-linked kinase 1 (ILK1), or PTEN loss [36,37].
Activating mutations in PI3K or Akt, however, are uncommon also in AML [36].
• Patients are heterogeneous with regard to the effect of PI3K-Akt-mTOR inhibitors on AML cell
proliferation; although an antiproliferative effect is observed for most patients, no effect or even
growth enhancement is seen for a subset of patients [27]. This adverse effect is possibly associated
with differences in cell cycle regulation.
• There seems to exist several escape mechanisms to inhibition of this pathway [1]. Firstly, induction
of autophagy during treatment may represent a mechanism of resistance, and combination of
PI3K-Akt-mTOR and autophagy inhibitors has therefore been suggested. Secondly, paradoxical
Akt phosphorylation during treatment may induce expression and autophosphorylation of the
receptors for insulin, IGF-1 and PDGF resulting in increased pathway activation. This feedback
effect can be blocked by PDGFR/IGF-1R/Flt3 inhibition. Thirdly, activation of MAPK-interacting
kinases can increase eukaryotic translation initiation factor E4 (eIF4E) phosphorylation and
thereby trigger synthesis of pro-survival proteins. Finally, increased signalling of alternative
pathways (e.g., ERK upregulation) can also be seen. These observations clearly illustrate the
intracellular complexity of PI3K-Akt-mTOR inhibition.
• New mTOR inhibitors seem to target both TORC1 and TORC2, whereas the earlier inhibitors
targeted mainly TORC1; the more recent inhibitors may thereby have a stronger effect [23].
• 5′ AMP-activated protein kinase (AMPK) is an inhibitor of mTORC1; directly through inhibition
of raptor and indirectly through activation of the TSC1/TSC2 complex [41]. At starvation,
AMPK initiates increased fatty acid oxidation and also autophagy, and AMPK activation/agonists
have a cytotoxic effect in AML cells [25].
• The combination of conventional chemotherapy with PI3K-Akt-mTOR inhibitors seems to have
an acceptable toxicity, but further clinical studies are needed to clarify whether there are additive
or synergistic antileukemic effects [38].
Thus, PI3K-Akt-mTOR inhibition is a possible therapeutic strategy also in AML, but with AML
being a highly heterogeneous disease the effects may differ among subsets of patients.
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4. PI3K-Akt-mTOR in MSCs
4.1. Identification, Differentiation and Function of Bone Marrow MSCs
MSCs are pluripotent cells capable of self-renewal and differentiation into various cells of the
mesenchymal lineages. They were originally identified in vitro as plastic-adherent cells which are
able to differentiate into osteoblasts [42] and to form fibroblast colonies (CFU-F) [43]. MSCs are large
cells with prominent nuclei [44] and a fibroblast-like morphology [45,46] with mostly spindle-shaped
cells [47], but subpopulations of large flat or small round cells can often be detected [48]. Traditionally,
MSCs have been linked with the bone marrow (BM MSCs), but they can be isolated from almost
every type of connective tissue [47,49], e.g., adipose tissue, dental pulp, synovia, umbilical cord,
skeletal muscle in addition to peripheral blood [50–54]. MSCs make up between 0.001% and 0.01%
of BM mononuclear cells [50], which is even less than haematopoietic stem cells (HSC) that make up
approximately 1% of the BM cells [44].
MSCs are progenitors of cells of the mesenchymal lineages, i.e., osteoblasts, adipocytes,
chondrocytes [55], and also fibroblasts and pericytes [50]. However, MSCs have the capacity to
trans-differentiate [56], i.e., they can differentiate into lineages outside the mesenchymal remit [2].
So far, MSCs have been shown to trans-differentiate into various neural cells (neurons, astrocytes and
glial cells) [57,58], cardiomyocytes [59], skeletal [60] and smooth muscle cells [61], hepatocytes [48],
epithelial cells [56] and pancreatic cells [54]. MSCs make up a heterogeneous population with respect
to self-renewal and differentiation potential. Thus, not all MSCs fulfil the criteria of stem cells;
i.e., some cells show a higher lineage commitment and thereby a reduced self-renewal capability,
whereas other cells are more immature and resemble embryonic stem cells, so-called ESC-like cells [52].
MSCs also show reversible commitment, i.e., they can undergo re-differentiation into another lineage
in vitro [62,63].
The most important function of BM MSCs is to provide the environment for growth, maturation,
differentiation and survival of both normal and leukemic haematopoietic cells [56]. MSCs are also
recruited to sites of inflammation where they engraft and repair damaged tissue [2,50], they can
act as phagocytes and antigen-presenting cells (APCs) under immunostimulatory conditions [53,64],
and they can be recruited to tumours and support cancer cell growth and survival [2,65].
Previous studies have used MSCs isolated from different tissues and with varying potential of
self-renewal and differentiation; this is probably the reason why it has been difficult to reproduce the
results from many previous studies. The International Society for Cellular Therapy (ISCT) has therefore
defined three criteria that MSCs must fulfil: plastic adherence under standard culture conditions,
expression of several distinct clusters of differentiation (CDs) and the absence of several haematopoietic
markers (see Section 6); and finally, the ability to differentiate into bone, fat and cartilage in vitro [66].
This review focuses on the surface markers of MSCs, their communication with neighbouring cells
through constitutive cytokine release and finally, the importance of PI3K-Akt-mTOR signalling for MSC
proliferation, differentiation and communication with neighbouring BM cells, including AML cells.
4.2. MSC Contributions to Stem Cell Niches in the Bone Marrow
BM MSCs are located mainly within the vasculature, on the surface of the main sinusoidal
blood vessels [64], and on the trabeculae [56] where they provide the environment for regulation of
haematopoietic stem cell proliferation and quiescence [48,62]. The haematopoietic microenvironment
is established by mesenchymal stromal elements which form a complex network of cells, extracellular
matrix glycoproteins and growth factors released by the stromal cells [67]; the latter consists of
ECs, adipocytes, macrophages, reticular cells, fibroblasts, osteoprogenitors and haematopoietic stem
cells with their progeny [62]. The microenvironments, also called niches, embed haematopoietic
stem cells and more mature blood cells and protect these cells from differentiation and apoptotic
stimuli, thus providing a surrounding for stem cell maintenance and self-renewal [68]. These stem
cell niches can be defined as the cellular and molecular microenvironments that regulate stem cell
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function together with stem cell autonomous mechanisms including the control of the balance between
quiescence, self-renewal and differentiation, and responsiveness to environmental stress. The marrow
niche is formed by perivascular MSCs together with macrophages, sinusoidal ECs, sympathetic nerve
fibres, and cells of the osteoblastic lineage (Figure 2) [3]. The MSCs thereby contribute to the control of
stem cell differentiation and the subsequent release of their mature progenies [47].Molecules 2016, 21, 1512 7 of 31 
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Figure 2. The contribution of MSCs to the microenvironment of bone marrow stem cell niches. Several
cell types contribute to the stem cell niches, especially the osteoblasts, MSCs and ECs. The MSCs are
localized both close to the sinusoids where they seem to contribute to the regulation of cell trafficking
across the v ssel wall, and the extravascular space between th v ssels and clos to the osteoblasts
in the endosteum where they also release extracellular matrix molecules. Thus, MSCs a e important
both for the extravascular microenvironment of the HSCs and for cell trafficking to and from this
microenvironment. Monocytes/macrophages and sympathetic nerve fibres are also important for the
supportive functions of the stem cell niches; these components are not shown in the figure.
The best characterized marrow niches are t e endosteal and vascular niches [62]. MSC-derived
osteoblasts, especially the more immature osteolineage cells [69], are the crucial elements of the
endosteal niche through the regulation of the stages of haematopoietic development [53] and the
control of the quiescent (G0) stage [47]. Additionally, the amount of haematopoietic stem cells within
the marrow is affected by changes in the loc l osteoblast numb r and function [70]. The vascular or
endothelial niche contains discrete areas of endothelium which circulating hematopoietic stem cells
preferentially home and engraft to [70]. Thus, in this microenvironment stem cell maintenance [69]
and recruitment as well as proliferation and differentiation is regulated [47]. Osteoblasts control the
myeloid differentiation of primitive stem cells and the differentiation of B-cells through excretion of
granulocyte-colony stimulating factor (G-CSF). On the other hand, adipocytes are negative regulators
of stem cell content nd function in the marrow [71]. Experime tal studies suggest th t both
osteoblast, fibroblasts and microvascular ECs can support leukemic haematopoi sis (i.e., AML cell
proliferation) [72–76], and the vascular niche is also a supportive environment for tumour cells [70]
and thereby a frequent site for tumour spread [77]. Finally, MSCs are located close to the sinusoid
and are therefore supposed to have a gate-keeper function, i.e., cells entering and leaving the marrow
have to by-pass and/or engage with MSCs [64,78]. Thus, MSCs might be actively involved in BM
homeostasis as a first line of the immune response [78], e.g., increased release of HSCs into circulation
during infections [53]. Cell trafficking leading to release of normal or leukemic cells to peripheral
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blood as well as homing of circulating tumour cells to the BM also involve MSCs. However, in spite of
the well-established view of niches, the true identity of the MSCs and contribution to the niches in vivo
is still under debate [52]. For example, MSCs close to blood vessels resemble pericytes in appearance
but possess the unique properties and functions of MSCs [45].
5. The AML-Supporting Effects of Mesenchymal Stem Cells: Contributions from Cell-Cell
Contact and Distant Effects Mediated through the Local Cytokine Network
Several signalling pathways are involved in MSC differentiation together with PI3K-Akt-mTOR,
including Bone Morphogenetic Protein (BMP) signalling, the Wingless (Wnt) pathway and Hedgehog
signalling (Figure 3). Most pathways exhibit an inverse relationship on differentiation, i.e., they support
differentiation into one lineage and suppress other lineages [79].
Molecules 2016, 21, 1512 8 of 31 
 
5. The AML-Supporting Effects of Mesenchymal Stem Cells: Contributions from Cell-Cell 
Contact and Distant Effects Mediated through the Local Cytokine Network 
Several signalling pathways are involved in MSC differentiation together with PI3K-Akt-mTOR, 
including Bone Morphogenetic Protein (BMP) signalling, the Wingless (Wnt) pathway and Hedgehog 
signalling (Figure 3). Most pathways exhibit an inverse relationship on differentiation, i.e., they 
support differentiation into one lineage and suppress other lineages [79]. 
 
Figure 3. Mesenchymal stem cell self-renewal and differentiation. Transforming growth factor β 
(TGF-β) and Wingless (Wnt) inhibitor Dickkopf-1 (DKK-1) contribute to MSC self-renewal; whereas 
signalling through PI3K-Akt-mTOR, Wnt, Hedgehog and bone morphogenetic protein (BMP) is 
involved in MSC differentiation into the three mesenchymal lineages and furthermore trans-
differentiation into myoblasts and neurons. Pathways that inhibit the differentiation into a specific 
lineage are marked with crosses (e.g., Wnt prevents adipogenesis). 
5.1. Regulation of MSC Differentiation Is More Than PI3K-Akt-mTOR—The Importance of BMP, Wnt and 
Hedgehog Signalling 
BMPs are multifunctional cytokines that belong to the transforming growth factor β (TGF-β) 
superfamily, and this family together with the Wnt pathway are crucial for MSC development and 
maintenance [80]. TGF-β and Wnt cooperatively stimulate MSC self-renewal and inhibit differentiation 
into osteoblasts and adipocytes [81]. In concurrence with this, inhibition of TGF-β leads to osteoblast 
[82,83] and adipocyte differentiation with suppressed chondrogenesis [84]. On the other hand, BMP-2 
promotes osteogenesis [85] and enhances osteoblast function [86]. The lineage commitment also 
depends on cell density: at a low cell concentration, the BMP pathway leads to adipogenesis, whereas 
a high cell density favours differentiation towards osteoblasts and chondrocytes [55,87]. Interestingly, 
both MSCs and osteoblasts themselves produce proteins of the TGF-β superfamily [79], and MSCs 
also express at least four Wnt members [82]. The Wnt pathway as well as the Hedgehog pathway 
stimulate osteogenesis while suppressing adipogenesis [79], and the Wnt inhibitor Dickkopf-1 
enables MSCs to enter the cell cycle, thus inhibiting osteoblast differentiation [88]. The Wnt3a protein 
promotes MSC self-renewal by increasing proliferation while simultaneously decreasing apoptosis 
and osteogenesis [62]. 
5.2. The General Effect of PI3K-Akt-mTOR Signalling on MSC Differentiation 
Adipogenic and osteogenic differentiation are controlled by IGF-1R via its direct or indirect, 
activation of PI3K, PDK-1, Akt and mTOR [79]. A critical level of Akt activity is required for 
adipogenesis [79], and PI3K, Akt, mTORC1 and S6K1 are all activated during adipogenesis [89]. The 
PI3K-Akt-mTOR pathway is also a positive regulator of terminal adipocyte differentiation [89], 



















Figure 3. Mesenchymal stem cell self-renewal and differentiation. Transforming growth factor
β (TGF-β) and Wingless (Wnt) inhibitor Dickkopf-1 (DKK-1) contribute to MSC self-renewal;
whereas signalling through PI3K-Akt-mTOR, Wnt, Hedgehog and bone morphogenetic protein
(BMP) is involved i MSC differentiation into the three mesenchymal lineages and furthermore
trans-differentiation into myoblasts and neurons. Pathways that inhibit the differentiation into a specific
lineage are marked with crosses (e.g., Wnt prevents adipogenesis).
5.1. Regulation of MSC Differentiation Is More Than PI3K-Akt-mTOR—The Importance of BMP, Wnt and
Hedgehog Signalling
BMPs are multifunctional cytokines that belong to the transformi g growth factor β (TGF-β)
superfamily, and this family together with the Wnt pathway are crucial for MSC development
and maintenance [80]. TGF-β and Wnt cooperatively stimulate MSC self-renewal and inhibit
differentiation into osteoblasts and adipocytes [81]. In concurrence with this, inhibition of TGF-β
leads to osteoblast [82,83] and adipocyte differentiation with suppressed chondrogenesis [84]. On the
other hand, BMP-2 promotes ost ogen sis [85] and hances osteoblast function [86]. The lineage
commitment also depends on cell density: at a low cell concentration, th BMP thway leads
to adipogenesis, whereas a high cell density favours differentiation towards osteoblasts and
chondrocytes [55,87]. Interestingly, both MSCs and osteoblasts themselves produce proteins of the
TGF-β superfamily [79], and MSCs also express at least four Wnt members [82]. The Wnt pathway
as well as the Hedgehog pathway stimulate osteogenesis while suppressing adipogenesis [79],
and the Wnt inhibitor Dickkopf-1 enables MSCs to enter the cell cycle, thus inhibiting osteoblast
differentiation [88]. The Wnt3a protein promotes MSC self-renewal by increasing proliferation while
simultaneously decreasing apoptosis and osteogenesis [62].
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5.2. The General Effect of PI3K-Akt-mTOR Signalling on MSC Differentiation
Adipogenic and osteogenic differentiation are controlled by IGF-1R via its direct or indirect,
activation of PI3K, PDK-1, Akt and mTOR [79]. A critical level of Akt activity is required for
adipogenesis [79], and PI3K, Akt, mTORC1 and S6K1 are all activated during adipogenesis [89].
The PI3K-Akt-mTOR pathway is also a positive regulator of terminal adipocyte differentiation [89],
whereas S6K1 is important for commitment to the adipogenic lineage [90]. Concurrent with these
observations, both rapamycin [2,89,91] and the loss of raptor [22] reduce adipogenesis, whereas the
loss of rictor promotes adipogenesis on behalf of osteogenesis [22]. Additionally, mTORC1 is
required for osteoblast proliferation and differentiation, and also regulates osteoblastic function [2].
The PI3K-Akt-mTOR and the BMP pathways (see below) interact; BMP-2 activates Akt to induce
osteoblast differentiation and also activates PI3K in osteoblasts, whereas PI3K and Akt are required
for the expression of the BMP-2 osteoblast differentiation marker and are also necessary for the
transcription of BMP-2 [86]. Finally, regarding differentiation into unrelated germline lineages,
both mTOR complexes as well as PI3K seem to be involved in myogenesis [2,86], whereas BMPs
suppress this differentiation [83]. Other lineage differentiations, like those into neural, pancreatic and
endothelial cells seem to be effects of silenced or forced expression of single transcription factors [54],
but differentiation into neurons has also been correlated with mTOR [2].
5.3. The Unique Membrane Molecule Profile of MSCs: Possible Molecular Mechanisms for Communication
with Neighbouring Cells through Direct Cell-Cell Contact and via the Local Cytokine Network
MSCs express a variety of surface markers and receptors but no single marker is MSC-specific
(Table 2) [50,52,53,80,92,93]. These markers include several molecules involved in cell-cell and
cell-matrix contact, receptors for soluble mediators and various enzymes that can modulate intercellular
communication. According to the ICST criteria [66] a MSC cell population has to show at least 95% of
CD73+ (ecto 5′ nucleotidase), CD90+ (Thy-1) and CD105+ (endoglin) cells, whereas less than 2% of
cells may express the pan-leukocyte marker CD45, the immature haematopoietic cell marker CD34,
the monocyte/macrophage markers CD11b and/or CD14, the B-cell markers CD19 and/or CD79,
and major histocompatibility complex (MHC) class II HLA-DR molecules; the latter are only expressed
after MSC stimulation with for example interferon γ (IFN-γ) [66]. MSCs have furthermore been
proposed to be negative for several other markers commonly expressed on other lineages (summarized in
Table 1): endothelial progenitor marker CD31 (PECAM-1) [94], myeloid marker CD15 (SSEA-1) [95],
haematopoietic marker CD133 [96], T-cell markers CD3, CD4 and CD8, natural killer (NK) cell marker
CD56 (NCAM) [95], B-cell markers CD80 [47], antigen-presenting cell markers CD40 and CD86 [93],
erythrocyte marker CD235a [80], and CD117 [94].
Table 2. The cell surface molecular profile of human MSCs; an overview of different molecules.
The molecules suggested to be used for identification of MSCs are marked in bold.
Adhesion Molecules and Other Cell Surface Molecules Involved in Local Cell-Cell or Cell-Matrix Contact
CD90: Thy-1 A cell surface glycoprotein and member of the immunoglobulin superfamily involved incell adhesion and cell communication in numerous cell types, including stem cells.
CD29: Integrin β1 [48]
Integrins are heterodimeric proteins that mediate bidirectional communication across the
cell membrane. They are made up of α and β subunits. At least 18 α and eight β subunits
have been described. This protein is a β subunit.
CD31: PECAM-1 [55] This is a cell surface protein; it can be a part of intercellular junctions and is probablyinvolved in leukocyte migration and integrin activation.
CD44: HCAM [50]
This cell-surface glycoprotein is a receptor for hyaluronic acid and is involved in cell-cell
interactions, cell adhesion and migration. It can also interact with other ligands, such as
osteopontin, collagens, and matrix metalloproteinases (MMPs).
CD48a/e/f: Integrins
α1/α5/α6 [48,52]
These integrins are members of the immunoglobulin-like receptor family; it does not
have a transmembrane domain, however, but is held at the cell surface by a GPI anchor
via a C-terminal domain which may be cleaved to yield a soluble form of the receptor.
CD54: ICAM-1 [97] This cell surface glycoprotein binds to integrins of type CD11a /CD18, or CD11b/CD18.
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Adhesion Molecules and Other Cell Surface Molecules Involved in Local Cell-Cell or Cell-Matrix Contact
CD56 NCAM [48] This cell adhesion protein is a member of the immunoglobulin superfamily, and it isinvolved in cell-cell as well as cell-matrix interactions.
CD62L/P: L/P-selectin [55]
CD62P: This 140 kDa membrane protein is a calcium-dependent receptor that binds to
sialylated forms of carbohydrate antigens. CD62L: This cell surface adhesion molecule
can mediate binding of leucocytes.
CD106: VCAM-1 [98] This member of the Ig superfamily is a cell surface sialoglycoprotein mediating cell-celladhesion and signal transduction.
CD146: MCAM [98] Probably acting as a cell adhesion molecule.
Cadherin-11/Cadherin-2 [48]
Cadherin-11 is a type II classical cadherin from the cadherin superfamily, integral
membrane proteins that mediate calcium-dependent cell-cell adhesion. Type II (atypical)
cadherins are defined based on their lack of a HAV cell adhesion recognition sequence
specific to type I cadherins. This cadherin seems to have a specific function in bone
development. Cadherin-2 is a classical cadherin, i.e., a calcium-dependent cell adhesion
molecule and glycoprotein.
Cell Surface Cytokine Receptors
CD95: Endoglin RNG A homodimeric transmembrane protein, it is a component of the transforming growthfactor β (TGF-β) receptor complex
CD71: Transferrin receptor
protein 1 [47]
This cell surface receptor is necessary for cellular iron uptake by the process of
receptor-mediated endocytosis.
CD117: c-Kit [99] This protein is the receptor for the stem cell factor (SCF).
CD135: Flt3 [55] This receptor is activated by binding of the Flt3 ligand.
CD166: ALCAM [46] This protein is a member of a subfamily of immunoglobulin receptors and is a CD6receptor; it is implicated in cell migration.
CD271: LNGFR [96] This is the nerve growth factor receptor.




These are all chemokine receptors that can bind a wide range of CCL and CXCL
chemokines; mediators which are important regulators of cell trafficking, cell cycle
progression and cell survival.
Enzymes
CD73: ecto 5′ nucleotidase A plasma membrane protein that catalyses the conversion of extracellular nucleotides tomembrane-permeable nucleosides.
CD10: Neprilysin [96] A glycoprotein that is a neutral endopeptidase that cleaves peptides at the amino side ofhydrophobic residues and inactivates several peptide hormones
CD13: Alanine
aminopeptidase [96]
A plasma membrane protein; the large extracellular carboxy-terminal domain contains
a pentapeptide consensus sequence characteristic of members of the zinc-binding
metalloproteinase superfamily. The enzyme was thought to be involved in the
metabolism of regulatory peptides.
Thrombospondin [48] This protein has several distinct regions, including a metalloproteinase domain,a disintegrin-like domain, and a thrombospondin type 1 motif.
Additional MSC-Expressed Molecules
CD157: Stromal cell
antigen [95] This glycosylphosphatidylinositol-anchored molecule can facilitate cell growth.
Nestin [52] This protein is a member of the intermediate filament protein family.
Sox-2 [50] This protein is a member of the SRY-related HMG-box (SOX) family of transcriptionfactors required for stem-cell maintenance.
OCT-4 [50] This transcription factor is important for stem cell pluripotency.
The following MSC markers have also been described in previous studies: GD-2 [48], STRO-1 [67], 3G5 [52],
SSEA-3 [52] and SSEA-4 [80]. Abbreviations: CAM: cell adhesion molecule; PECAM: platelet endothelial CAM;
HCAM: haematopoietic CAM; ICAM: intracellular AM; NCAM: neural CAM; VCAM: vascular CAM; MCAM:
melanoma CAM; ALCAM: activated leukocyte AM; LNGFR: low-affinity nerve growth factor receptor; SSEA:
stage-specific embryonic antigen.
However, among these markers CD31 [55], CD56 [48] and CD117 [99] have also been proposed as
potential MSC markers, with CD56 possibly being a stemness-maintaining factor [48]. Furthermore
CD105 is a marker that has to be present on MSCs, but it is also expressed by ECs and pre-mature
B-cells [96]. These observations further illustrate that combinations of markers have to be used to
identify MSCs. There is also a long list of membrane molecules that can be expressed by MSC or subsets
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of MSCs (recently reviewed in [52]), including: CD10 (neprilysin), CD13 (alanine aminopeptidase) [96],
CD71 (transferrin receptor protein 1) [47], cytokine receptor CD135 (Flt3) [55], BM stromal cell antigen
CD157 [95], CD271 (LNGFR) [96], CD349 (frizzled-9) [52], HCAM (CD44) [50], VCAM-1 (CD106),
MCAM (CD146) [98], ALCAM (CD166) [46], ICAM [97], STRO-1 [67], the neural ganglioside GD2 [48],
pericyte marker 3G5, SSEA-3 [52], SSEA-4 [80], cadherin-11, N-cadherin (CD325) [48], L- and P-selectin
(CD62L/P) [55], thrombospondin-1 [48], and integrins α1, α5, α6 and β1 (CD49a/e/f and CD29,
respectively) [48,52,95]. MSCs also express some intracellular markers like nestin [52], sex-determining
region Y-box 2 (Sox-2) and octamer-binding transcription factor 4 (OCT-4) [50], and a variety of
chemokine receptors [93–95,100].
There is no general agreement about which of the markers that are best in determining stemness.
Some authors advise not to use universally expressed markers that are not unique for this cell
type; this includes 3G5, GD-2, CD349, CD271, STRO-1 and SSEA-4, even though the last three are
important for MSC clonogenecity and function [52], and SSEA-4 can be useful for separating MSCs
from HSCs [80]. On the other hand, the cadherins, integrins and thrombospondin have potential as
stemness markers [48] and are associated with clonogenecity and multipotency [52]. The presence
of VCAM-1 indicates that cells are multipotent and support haematopoiesis; it is also expressed by
most MSCs, and might thus be the most suitable stemness marker [48,52]. The most immature MSCs
express several markers that are lost upon commitment and may thus be used to identify a subset of
pluripotent MSCs; these markers are SSEA-3 [52], Sox-2, OCT-4 [50] and, probably, nestin [52].
MSCs do not only lose primitive stemness markers upon differentiation but also upon passaging
in vitro [80,95,96], including the chemokine receptor CXCR4 which is important for cell migration [45,97].
Several markers are also lost when cells reach confluence [52]; and at the same time the cells may lose
their differentiation potential [48]. However, certain markers can also be gained, both in vitro [80,95,96]
and in the BM niches [44].
MSC homing involves several molecular mechanisms [45,99], including various chemokines [47]
and adhesion molecules [80]. The most important chemokine, which is expressed at low concentrations
by MSCs themselves, seems to be CXCL12; this CXCR4-ligand induces MSC homing, migration and
marrow engraftment [99,101] in a dose-dependent manner [102]. MSCs adhere to ECs [80,98], and both
integrins and the adhesion molecules P-selectin and VCAM-1 are important for their adhesion to
endothelium [93]. However, MSCs do not only migrate to the BM [94], they also have multi-organ
homing capacity [68] and can migrate to lymphoid organs through CCR7 and CXCR5 ligation, to the
skin through CCR4 and CCR10 ligation, and to the small intestine and salivary glands through CCR10
ligation [100]. They also show chemokine-mediated migration to sites of wound healing and tissue
regeneration [78] where they provide a microenvironment favouring tissue regeneration [103].
5.4. The Functional Importance of PI3K-Akt-mTOR Signalling in MSCs: The Effects on MSC Differentiation
Are Only a Part of a More Extensive and Complex Biological Impact
The PI3K-Akt-mTOR pathway is important for the regulation of several biological characteristics
of the MSCs; the current knowledge is described more in detail in Table 3 [2,76,91,104–134]. Firstly,
the pathway is important for stress responses, including the adaptation of the MSCs to the hypoxic
BM microenvironment. It is also important for regulation of MSC metabolism and induction of
autophagy. Secondly, MSCs show functional differences depending on the patients’ age, and altered
activation of the pathway is involved in the process of aging and age-dependent differences of BM
MSCs. Thirdly, the various parts of this pathway are also involved in the process of MSC differentiation.
The most important differentiated mesenchymal cells in the BM are AML supporting osteoblasts and
adipocytes [72], and the PI3K-Akt-mTOR network is important for the balance between osteogenic and
adipogenic differentiation. Finally, the pathway contributes to the regulation of MSC communication
between MSCs and their neighbouring cells, including more differentiated AML-supporting cells
(e.g., osteoblasts and fibroblasts).
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Table 3. PI3K-Akt-mTOR signalling in MSCs; the effects on important biological functions.
Aging of MSCs: PI3K-Akt-mTOR Inhibition Maintains an Immature State
BM MSCs show decreased self-renewal, differentiation and function with aging; inhibition of the PI3K-Akt-mTOR pathway preserves the immature state and prevents the
development of the age-related phenotype [109]. Increased expression of the transcription factors NANOG and OCT-1 may be responsible for this. Furthermore, a comparison
of BM MSCs for younger (<30 years of age) and elderly (>70 years of age) individuals showed increased expression of genes associated with mTOR signalling [123]. Studies of
both murine and human BM MSCs have shown that miR-188 regulates the age-related switch between osteoblast and adipocyte differentiation, and miR-188 then targets
rictor [116].
Animal studies have shown decreased BM levels of IGF-1 in aged rats; IGF-1 seems to stimulate osteoblastic MSC differentiation through activation of mTOR and aging of
MSCs may thus be caused by decreased mTOR signalling [131].
Metabolic Regulation
MSC proliferation is regulated by extracellular glucose levels; this effect is mediated through both the PKC-MAPK and PI3K-Akt-mTOR pathways [124].
Glycogen synthase kinase 3 β is a metabolic regulator; inactivation of this regulator can be caused by signalling through mTORC2 and Akt phosphorylation at S437 [104].
Differentiation of MSCs—General Effects
Murine studies suggest that absence of mTORC1 causes reduced capacity of adipocyte differentiation, whereas absence of mTOCR2 causes reduced osteogenic differentiation
capacity and accelerated adipogenesis [91,126].
mTORC2 regulates mechanically induced cytoskeletal reorganization (actin stress fibre development) and favours osteogenesis over adipogenesis [126].
The stemness marker CD49f identifies a subset with high proliferative ability and differentiation potential; downregulation of this marker (i.e., knockdown, tumour necrosis
factor α, TNF-α, treatment) is associated with decreased differentiation and downregulation through TNF-α is mediated by mTOR [132].
Osteogenic Differentiation of MSCs
IGF-1-induced growth enhancement and osteoblastic differentiation of MSCs is inhibited by mTORC1 inhibitor rapamycin; this IGF-1effect is seen for MSCs derived from
different tissues including BM [106,131].
The osteogenic effect of erythropoietin is mediated through various intracellular pathways, including signalling through PI3K and mTOR [113,125].
There seems to be a time-dependent modulation of AMPK-Akt-mTOR signalling during osteogenic differentiation with early activation of AMPK/raptor and thereby
mTOR/S6K1 inhibition, and later activation of Akt/mTOR [120].
Stat3 activation seems to be a negative regulator of osteogenic differentiation [115]. BMP-2 and -4 stimulate osteogenic differentiation; JAK2 signalling then
mediates Stat3 tyrosine phosphorylation whereas serine phosphorylation is mediated through ERK1/2 and mTOR signalling. Stat3 knockdown accelerates and augments
osteogenic differentiation.
mTOR inhibitors can increase osteogenic differentiation [119], and studies in human BM MSCs suggest that osteopenia can be induced through PI3K-Akt-mTOR and
activation of S6K1 [118]. However, the effects of the PI3K-Akt-mTOR pathway are complex and effects of pathway inhibitors are difficult to predict. Induction of osteogenic
differentiation has not been detected in all experimental models, and a possible explanation is that the final effect of mTOR inhibitors depends on the experimental model and
the biological context [2]. However, the dual PI3K/mTOR inhibitor BEZ235 strongly inhibited osteogenic differentiation in human MSCs [119].
Adipocytic Differentiation of MSCs
Adipocytic differentiation is associated with downregulation of Notch gene expression; modulation of PTEN-PI3K-Akt-mTOR signalling seems important for this
Notch effect [127].
Insulin, Akt and mTOR signalling is important in adipocyte differentiation and rapamycin can reduce the expression of most adipocyte markers [2]. mTOR is essential for
adipocytes to sense nutrient availability and modulation of PPAR-γ activity that is an important regulator of the adipogenic gene expression program [2].
Differentiation of brown adipocytes requires signalling pathways distinct from white adipocytes; mTOR activity is involved in the initial steps but later inhibition through
AMPK activation is also necessary [2].
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Table 3. Cont.
Myogenic Differentiation
A recent review concluded that several studies suggest that mTOR is indispensable for myogenesis, but the mechanisms behind this function are largely unknown [2].
Regulation of Autophagy and Senescence in MSCs
Autophagy is the natural regulated mechanism that disassembles unnecessary or dysfunctional cellular components. Cellular senescence is the phenomenon by which normal
diploid cells cease to divide, but they remain metabolically active and commonly adopt an immunogenic phenotype consisting of a pro-inflammatory secretome.
These two processes seem to be regulated by overlapping mechanisms. AMPK is a positive regulator of autophagy in MSCs; autophagy can then be activated through the
AMPK-mTOR pathway and protect BM MSCs from stress-induced apoptosis [133].
Animal studies suggest that senescent BM MSCs show upregulation of p53 and downregulation of mTOR. Knockdown of p53 then alleviates senescence, reduces autophagy
and upregulates mTOR [134].
Human BM MSCs show downregulation of Notch gene expression during adipocyte differentiation; Notch inhibition will also enhance adipocyte differentiation and at the
same time induce autophagy by acting on the PTEN-PI3K-Akt-mTOR pathway [127]. mTOR inhibition can also reverse the senescent phenotype of human MSCs [110].
Thus, the PI3K-Akt-mTOR pathway is involved in the regulation of senescence/autophagy/apoptosis in BM MSCs.
Adaptation to the Hypoxic BM Microenvironment
The BM microenvironment is hypoxic [105,107,111]; the hypoxia seems to causes upregulation of hypoxia-inducible factor 1α (HIF-1α) in primary human AML cells and
increased constitutive release of several cytokines by the leukemic cells [112]. Hypoxia induces autophagy and eventually apoptosis in BM MSCs; at the same time hypoxia
seems to activate AMPK-mTOR signalling and inhibition of mTOR will then further increase the hypoxia-induced apoptosis [134]. However, hypoxia stimulated by Toll-like
receptor (TLR) ligation show decreased apoptosis in response to hypoxia and at the same time increased autophagy and activated AMPK-mTOR signalling [117].
Furthermore, downregulation of leptin will attenuate hypoxia-induced autophagy [128]. Finally, hypoxia also increases the levels of fatty acid synthetase in umbilical cord
MSCs; increased signalling through HIF-1α-fatty acid synthase-mTORC1 then represents an important link between hypoxia-induced lipid metabolism and increased
proliferation as well as migration of MSCs [114]. Thus, autophagy seems to protect MSCs against hypoxia-induced apoptosis; AMPK-mTOR signalling seems important for
regulation of autophagy and thereby also for the adaptation of MSCs to a hypoxic BM microenvironment together with leptin and possibly p53 (see above).
Communication between MSCs and Neighbouring Cells
Fibroblasts: Fibroblasts can support AML cell proliferation; they also show constitutive release of leukaemia-supporting/angioregulatory cytokines and this release can be
altered by PI3K/mTOR inhibition [76]. Conditioned medium from cultures of BM MSCs suppresses fibroblast proliferation; this effect is mediated mainly by TGF-β3 [130].
However, MSCs release a wide range of soluble mediators and other forms of TGF-β that signal through the same receptors [108]; probably, other cytokines/chemokines may
also contribute to this effect. PI3K-Akt-mTOR signalling is a downstream effect to TGF-receptors, and this pathway is also important for fibroblast proliferation
(both mTORC1 and mTORC2), adherence and release of extracellular matrix molecules [108,121,122,129]. Thus, PI3K-Akt-mTOR targeting may alter this crosstalk between
MSCs and fibroblasts both through effects on MSCs and the fibroblasts.
Osteoblasts: mTOR/S6K1 signalling is important for osteoblast responses to exogenous cytokines and for the regulation of osteoblast cytokine release [2], including cytokines
that can support leukemogenesis and modulate other stromal cells including MSCs [2].
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Thus, PI3K-Akt-mTOR signalling is important both for aging, adaptation, differentiation,
communication and proliferation of BM MSCs, and even though the molecular mechanisms are only
partly known, one would expect PI3K-Akt-mTOR inhibition to alter the MSC functional characteristics
and thereby also affect the AML cell microenvironment including that of the stem cell niches. There is
a molecular crosstalk between AML cells and MSCs, and studies of the global gene expression
profiles suggest that for most patients this crosstalk results in an altered local cytokine network
mediated through effects on NFκB signalling but without induction of osteoblastic or adipogenic
differentiation [135]. It is not known how PI3K-Akt-mTOR inhibition will alter this crosstalk. Finally,
one would also expect differences among patients because even though previous studies of gene
expression suggest that the effects of this crosstalk on the MSCs are similar for most patients, there are
exceptional patients showing distinct effects of the AML-MSC crosstalk on gene expression [135].
5.5. Cytokine-Mediated Communication between MSCs and the Neighbouring Bone Marrow Cells; a Part of the
AML-Supporting Effects by the MSCs
MSCs release a wide range of cytokines (Table 4) that are important for communication with
neighbouring cells [47] or are parts of autocrine loops [48]. The cytokines are important for the support
of haematopoiesis [136,137], for initiating tissue regeneration [45,138] and for immunoregulation [51].
This constitutive release is a part of a bidirectional cytokine-mediated crosstalk between MSCs and
AML cells, and its final effect is to support the growth and survival of human AML cells, including
the long-term proliferating leukemic stem cells. This supporting effect is detected for most patients,
but there is also a minority of patients where this effect is not observed (Brenner, Revised Version submitted).
Table 4. Cytokines released by MSCs and malignant cells.
Soluble Mediators Released by MSCs
Interleukins
IL-1α/β [47], IL-6 [55,136], IL-10 [139,140], IL-15 [141]
Chemokines
CCL2 [94,95], CCL3 [94], CCL4 [95], CCL5 [94,95], CCL7 [53], CCL20 [95], CCL26 [53], CXCL1 [53], CXCL2 [53],
CXCL5 [53], CXCL8 [94,136], CXCL10 [53], CXCL11 [53], CXCL12 [94,95], CX3CL1 [95]
Growth factors
Ang-1 [94], VEGF [94,136], TGF-β [139,140,142], PDGF [50], bFGF [50], FGF7 [50], HGF [139,140,142], IGF-1 [45],
EGF [45], G-CSF [55], M-CSF [55], GM-CSF [55], SCF [55], LIF [55], IFN-β [136]
Other mediators
PGE2 [139,140,142]
Soluble Mediators Commonly Released by Various Malignant Cells
IL-6 [93,143], Ang-1 [144], VEGF [144], TGF-β, BMP-4 [143], Wnt5α [144], Gremlin-1 [144], bFGF [143,144],
HGF [143], IGF-I/II [143], EGF [144], CTGF [143], G-CSF [144], CCL5 [93,143], CXCL12 [93,143]
Abbreviations: IL: interleukin; Ang-1: angiopoietin 1; G/M-CSF: granulocyte/macrophage-colony-stimulating
factor; LIF: leukaemia inhibitory factor; PGE2: prostaglandin E2; CTGF: connective tissue growth factor.
6. Direct Effects of PI3K-Akt-mTOR Inhibition on Immunocompetent Cells and the Dual
Function of Monocytes/Macrophages as Immunocompetent Cells and Members of the Stem
Cell Niches
Several soluble mediators derived from MSCs are probably important for their immunoregulatory
functions [53,78,101] and the MSC-induced downregulation of various immunocompetent cells [53].
The most important effects on T-cells, B-cells, monocytes/macrophages and dendritic cells are
summarized in Table 5 and Figure 4 [45,47,51,53,68,71,78,80,88,93,136,137,139–142,145–152]. The effects
on T cells are best characterized and some of the other effects may be indirectly caused by T cell
inhibition. The BM niche provides a supporting environment for the development of immature T-cells
outside the thymus [153], and MSCs can suppress T-cell proliferation [68,137,154] and activation [53].
The inhibition of naïve and memory T-cells seems to be independent of MHC molecules [101] and may
involve a proapoptotic effect [68,154], T-cell anergy [80] and/or altered cell cycle regulation and cell
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cycle arrest in G0 or G1 phases [147]. The in vitro immunomodulation may involve both direct cell-cell
contact and soluble factors [97]. These effects are mainly characterized in experimental models, and it
has been suggested that these effects are less important in vivo due to the low number of MSCs [154].
Modulation of these MSC-associated immunoregulatory mechanisms may thereby indirectly alter the
function of a wide range of immunocompetent cells.
mTOR inhibitors are now used as immunosuppressive agents in clinical medicine; the rationale
for this is their direct effects on a wide range of immunocompetent cells leading to a final effect of
immunosuppression. The direct effects of PI3K-Akt-mTOR inhibition on immunocompetent cells have
been described in detail in recent reviews [155,156]. In our present article we will have a focus on the
monocytes that have a dual function as immunocompetent cells and as a part of the microenvironment
in the BM stem cell niches.
Table 5. Important effects of MSC on immunocompetent cells.
T Cells
• T-cell suppression may be induced by TGF-β, HGF, PGE2, IL-10, nitric oxide (NO) or the enzymes
indoleamine-2,3-dioxygenase (IDO) and haeme oxygenases (HOs) [68,80,93,139–142].
• PGE2 and IDO seem to have the strongest effects [88]: PGE2 forces macrophages to produce more IL-10,
and enhances the effect of IDO [45], whereas IDO inhibits proliferation through tryptophan degradation [88].
• The HO-1 effect is mediated through IL-10 and NO and is also regulated by IDO [139].
• NO is produced during chondrogenesis and inhibits Stat5 phosphorylation [142]. The effects of TGF-β and
IDO on T-cells are irreversible, whereas T-cell function can be restored after PGE2 exposure [142].
• MSCs also produce other potentially immunosuppressive factors, like IFN-β [136] and IL-1α/β [47].
• MSCs increase the number and trigger the activation of regulatory T-cells (Tregs) [51,149].
NK Cells
• Secretion of TGF-β, IL-15, PGE2 and IDO inhibits cytokine expression, proliferation and cytotoxicity of resting
NK cells [53,88,136,137,140,141].
• The final effect of MSCs on NK cells may depend on the cellular microenvironment because other studies have
described NK cell activation by MSCs [148].
B Cells
• The effect of MSCs on B-cells is still controversial [151], but MSCs seem to inhibit B-cell proliferation
[80,146,147] and modulate their function [140] through cell cycle arrest during G0 and G1 phases [88,146].
• MSCs also seem to inhibit B-cell differentiation, chemokine receptor expression and chemotaxis [146] through
soluble factors, e.g., PGE2 [53] and CCL2 [145], and cell-cell contact [45].
• MSCs have also been linked to enhanced B-cell differentiation [71].
• B-cell suppression may at least play an indirect role on T-cell suppression [47,136,150].
Dendritic Cells
• MSCs influence the differentiation of antigen-presenting DCs [53,78] by inhibiting DC maturation from
monocytes [88,141].
• MSCs also affect their activation by TLRs [152], their antigen presenting function [146] and their
anti-inflammatory potential [53].
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Figure 4. Immunosuppressive effects of mesenchymal stem cells. MSCs excrete various cytokines
that mediate immunosuppression of T-cells, B-cells, natural killer cells (NK) and dendritic cells (DC).
Some mediators, like prostaglandin E2 (PGE2), exhibit an immunosuppressive effect on all immune
cells, whereas others, like IL-15, are specific inhibitors of single cell types.
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6.1. PI3K-Akt-mTOR, MSCs and Immunocompetent Cells; Regulation of Allogeneic and Autologous
Antileukemic Immune Reactivity
Dependent on the activation state of the immune cells and cytokines they were exposed to—in
particular IFN-γ and TNF-α [157], MSCs might also contribute to a pro-inflammatory environment [152].
Cancer cells can alter the MSC cytokine expression profile towards a tumour-supporting
microenvironment [136,144]; this is similar to the effects on AML cells as described above. The soluble
factors influence several signalling pathways. For instance, IL-6 expression activates signalling
through Janus kinase 2 (JAK2) and Stat3 [158,159], EGF increases the concentration of pre-oncogenic
phosphorylated Akt [143], whereas CXCL12 and CCL5 stimulate tumour growth through the
PI3K-Akt-mTOR pathway [144]. CCL5 in particular has been linked with tumour cell proliferation and
metastasis [50]. TGF-β is expressed in tumour cells and tumour stroma and enhances tumour invasion
and metastasis, and also suppresses NK-cells [141]. However, MSCs may also induce the immune
response in order to reduce tumour growth by excretion of a variety of ILs in combination with IFN-γ
and G-CSF [160].
In allogeneic stem cell transplants, MSCs both enhance marrow engraftment and reduce the
risk of graft-versus-host-disease (GVHD) [84]; however, at the same time, they may increase
the risk of relapse due to a reduced graft-versus-leukaemia response [101]. Immune-mediated
antileukemic reactivity is best documented for allografted AML patients, but the experience from
autotransplanted patients suggests that autologous antileukemic immune reactivity may also be
important [161–163]. Furthermore, MSCs are used for suppression of autologous immune reactivity,
e.g., in the treatment of auto-immune diseases like Crohn’s disease [78], Parkinson’s disease and
diabetes [54]. Their differentiation potential makes them useful in repair and replacement of tissues [62],
both within and outside the mesenchymal lineages [54,82,92,94,164]. MSCs have also been proposed
as delivery vehicles that home to sites of injury or cancer [93,97]. Whether injected MSCs will support
or suppress human malignancies is difficult to predict and probably depends on factors like tumour
type, the MSC culture, the amount of engrafted cells and the tumour microenvironment [93,97].
6.2. The Role of AKT/mTOR as Regulators of Macrophage Metabolism and Cytokine Release
Macrophages and monocytes need to adapt to a wide variety of metabolic changes during
migration, cytokine production and differentiation, and the PI3K-Akt-mTOR pathway is a key regulator
in these processes. Classically, macrophages can be divided into non-polarized M0 macrophages
and the M1 and M2 macrophage phenotypes [165–167]. M1 macrophages are associated with acute
antimicrobial defence, production of pro-inflammatory cytokines (IL-6, IL-12 and TNF-α) and nitric
oxide (NO). M2 macrophages produce ornithine rather than NO and anti-inflammatory cytokines
(e.g., IL-10). Toll-like receptor (TLR) activation by stimulation through lipopolysaccharides (LPS)
triggers M1 differentiation via the NFκB pathway and interferon regulatory factors (IRFs), but also
through direct activation of the mTOR pathway. Stat6 and C/EBPβ activation by IL-4 and IL-13
are the main factors promoting M2 differentiation; both these mediators are directly affected by
mTORC1-mTORC2 regulated intracellular networks. Finally, PI3K also influences macrophage
functions via Janus kinases, p38 and ERK.
Cytokine production and metabolism are closely linked in macrophages. M1 macrophages
are characterized by glycolysis and a broken Krebs cycle with accumulation of citrate and succinate,
whereas M2 macrophages use aerobe glycolysis, β-oxidation and increased glutamine metabolism [168].
The accumulation of succinate in M1 macrophages is essential for IL-1β secretion through induction of
hypoxia inducible factor 1α (HIF-1α). In addition, lipidogenesis is necessary for adequate phagocytic
function, expansion of intracellular organelles and sustained cytokine production through the
production of inflammatory lipid mediators (e.g., prostaglandins) [169]. The role of Akt/mTOR
in these processes is not known but the following mechanisms have been suggested [156,169]:
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• Increased glycolysis in response to TLR stimulation can be mediated by Akt independent
of mTORC1.
• 4E-BP1 and 6SK1 have important roles in controlling the synthesis of both cytokines as well as
HIF-1α and IRF-7 that are necessary for the cytokine synthesis.
• Activation of sterol regulatory element-binding protein 1 (SRBP1) is important for synthesis of
lipid mediators and cytokines, and also for activation of the pentose-phosphate pathway that is
required for adequate respiratory burst.
• mTORC1 is critical for control of glutamine metabolism that again is a regulator of the hexosamine
pathway and the processes securing sufficient succinate accumulation.
Taken together these observations illustrate that PI3K-Akt-mTOR inhibition is likely to affect the
communication between monocytes and their neighbouring cells (e.g., AML cells), but the final effects
are difficult to predict and will probably depend on the mediator in the pathway being targeted.
6.3. The Role of Akt/mTOR in Macrophage Polarization—The Importance for AML Cells
and Immunoregulation
The role of the PI3K-Akt-mTOR pathway in macrophage differentiation has been investigated in
several murine knockout models (Table 6). Whether M1 or M2 polarization is induced depends on the
molecule to be targeted. Deletion or modulation of Akt through AMPK deletions lead to loss of M2
polarization accompanied by increased production of pro-inflammatory cytokines [170,171]. On the
other hand, deletion of PTEN leads to increased M2 polarization [172,173]. In addition, experimental
data suggest that different Akt isoforms have different effects with regard to macrophage polarization,
i.e., M1 polarization is Akt2-dependent whereas M2 polarization is Akt1-dependent [174,175], and the
Akt2 isoform selectively controls the C/EBPβ expression required for M2 polarization [174]. Finally,
TSC1/2 deletion downstream to Akt is associated with an inflammatory M1 phenotype [176–178],
whereas disruption of the mTORC1 complex by knockout of raptor leads to increased Akt activity and
increased M2 polarization [179]. These data clearly illustrate that whether PI3K-Akt-mTOR targeting
causes M1 or M2 polarization of monocytes depends on which mediators are targeted.
6.4. The Effect of Pharmacological Inhibition of Akt/mTOR in Macrophages
Pharmacological inhibition of the mTOR pathway has yielded conflicting results. Most studies
with mTOR inhibitors, however, have shown an increased secretion of pro-inflammatory cytokines
like TNF-α, IL-6 and CXCL8, reduced secretion of IL-10, inhibition of macrophage migration, failure to
polarize in the M2 direction and increased apoptosis of M2 cells (Table 7) [180–187]. These data
support the observation from clinical experience that mTOR inhibitors are associated with several
pro-inflammatory side effects [155], including increased systemic levels of several pro-inflammatory
cytokines even when mTOR inhibition is combined with steroids [188,189].
The in vivo effects of rapamycin on human M1/M2 also favours M1 polarization and induces
increased release of M1-type cytokines (CXCL9, CXCL10, IFN-γ, G-CSF and IL-1ra) in response to LPS
stimulation and reduced ability to develop in the direction of M2 polarization [185].
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Table 6. Effects on monocyte differentiation of knocking out single mediators involved in PI3K-Akt-mTOR signalling; the results from animal knockout models.
Media-TOR M1/M2 Ratio Comment Reference
Akt1 M1↑M2↓
Akt is expressed as the three different isoform Akt1, Akt2 and Akt 3. These isoforms contributes differentially to differentiation of
monocytes into the two main forms:
M1: Reduced responsiveness to TLR ligands, reduced secretion of IL-1βα, IL-6 and TNF-α.
M2: C/EBPβ seems important for M2 differentiation, Stat6 also seems to be involved together with miR-155.
The Akt1 isoform facilitates differentiation into the M2 phenotype, and Akt2 downregulation upregulates C/EBPβ.
Akt1 is important for Akt-mediated effects on ECs whereas Akt2 is important in insulin signalling.
[174]
Akt2 M1↓M2↑ Akt2 induces differentiation in direction of the pro-inflammatory M1 phenotype. [174,175]
AMPKα1 M1↓M2↑
AMPK activation in macrophages results in results in polarization to the anti-inflammatory M2 phenotype. Exposure of
macrophages to IL-10 causes AMPK activation, and AMPKα1 is then required for IL-10 activation of PI3K-Akt-mTORC1 and
Stat3-mediated anti-inflammatory pathways regulating macrophage polarization.
[171]
AMPKβ1 M1↓M2↑ Animal studies demonstrated that AMPKβ1 deficient macrophages are M1-activated, i.e., AMPK seems to differentiatemacrophages towards an immunosuppressive M2 phenotype. [170]
PTEN M1↓M2↑
PTEN is important for the increased release of pro-inflammatory cytokines such as IL-6 by macrophages in response to TLR
ligation, and deletion of PTEN then results in diminished inflammatory responses. Furthermore, macrophages isolated from such
knockout mice express higher levels of M2 markers, produce lower TNF-α and higher IL-10 levels in response to TLR ligation.
Such M2 macrophages also show enhanced Stat3- and Stat6-signalling together with diminished Stat1-signalling pathway
activation in response to TLR4 stimulation.
[172,173]
PDK1 M1↑M2↓ A major characteristic of mice with myeloid PDK1 knockout is increased tissue infiltration of macrophages with the M1 phenotype;the authors concluded that PDK1 regulates macrophage migration through inhibition of FOXO-1 induced CCR2 expression. [190]
Inpp5d M2↑
Inositol polyphosphate-5-phosphatase D. The expression of this protein is restricted to haematopoietic cells and it functions as
a negative regulator of myeloid cell proliferation and survival. Deficient murine monocytes are more sensitive to IL4-induced
induction of the M2 phenotype.
[191]
TSC1 M1↑M2↓
Knockout of TSC1 in the myeloid lineage causes constitutive mTORC1 activation with downregulation of Akt signalling that is
essential for resistance to M2 polarization and increased responsiveness to pro-inflammatory stimuli. Thus, the effect can at least
partly be explained by increased mTORC1 activity with a negative feedback on Akt function. The TSC1 deficient cells show
impaired migration and reduced expression of chemokine receptors, including CCR2 and CCR5, phagocytosis and reactive
oxygen species production is increased and the effect of the knockdown is partially reversed by mTORC1 inhibitors.
[176–178]
Raptor M1↓M2↑ Raptor deficiency reduced inflammatory gene expression in macrophages derived from several organs, including BMmacrophages. This seems to be caused by attenuation of Akt inactivation and increased NFκB signalling. [192]
Rictor M1↑M2↓ Primary macrophages isolated from myeloid-specific rictor null mice exhibited an exaggerated response to TLRs ligands,and expressed high levels of M1 genes and lower levels of M2 markers. [179]
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Table 7. The effect of mTOR inhibition on various biological characteristics of human monocytes/macrophages.
Hallmark Drug Cells Effect Reference
Cytokine Production Sirolimus THP-1 human AML monocytic cell lineNormal human monocytes
Sirolimus reduced release of CCL2, CCL3, CCL5 and CXCL8 in both human and
murine monocytes; CCL4 was in addition reduced in human cells. There was no
effect on TNF-α release.
[183]
Everolimus C57BL/6 murine cellsNormal human monocytes
While mTOR inhibition did not lead to any changes during starvation,
everolimus significantly increased production of IL-6, CCL2, CCL5 and TNF-α and
except for CCL2 this increase was inhibited by MAPK inhibition.
[184]
Rapamycin Normal human monocytes tested in vivoand in vitro
Rapamycin induced apoptosis of M2- but not M1 polarized cells.
M1 polarized: rapamycin reduced the release of CXCR4 and expression of CD206
and CD209; also reduced stem cell growth factor β, CCL4 and CCL13.
M2 polarized: rapamycin increased expression of CD86, CCR7, IL-6 and TNF-α;
reduced CD206, IL-10, VEGF and CCL18.
Stimulation by LPS, Listeria Pam3Cys or flagellin; increased release of IL12p40 and
IL-23, reduced TNF-α and IL-6.
[185]
Everolimus Rat monocytes, in vivo studies
Histological examination of induced experimental neuritis showed that everolimus
significantly (i) increased accumulation of M2 cells, spleen M2 cells were also
increased; (ii) mRNA levels of INF-γ and IL-17 were reduced whereas they
increased for TGF-β and IL-4; (iii) cytokine protein levels showed reduced IL-1α,
IFN-γ and CCL5 but increased IL-10 levels.
[181]
Rapamycin Human, in vitro Rapamycin decreased IL-6 and IL-10 but did not affect TNF-α release afterLPS exposure. [186]
In vivo migration Everolimus In vivo and in vitro studiesMonocytes
Everolimus reduced migration of macrophages to atherosclerotic plaque in the
carotis wall; in vitro studies showed reduced migration towards CCL2, CXCL3,
CXCL8, C5a and N-formylmethionyl-leucyl-phenylalanine.
[180]
Foam cells formation Everolimus THP-1 foam cells Decreased viability of foam cells, no effect on release of IL-1β, CXCL8, TNF-α butreduced release of CCL2; increase cellular clustering. [182]
Expression of TLRs Everolimus Normal human monocytes, in vitro studies A significant increase in TLR expression by monocytes was seen in patients withdrug eluting stents compared with bare metal stents. [187]
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7. Summarizing Discussion
7.1. The Complexity of PI3K-Akt-mTOR Signalling—What Is the Optimal Molecular Target for
Pathway Inhibition?
PI3K-Akt-mTOR is not only a pathway but a signalling network including feedback loops that
will alter the continued signalling; it will thereby be important which target within the pathway
that is selected for inhibition of the signalling. One example of this is the increased activation of
Akt that may be seen after mTOR inhibition; an effect which is not seen after PI3K inhibition and
these two strategies may thereby differ in the activation of alternative downstream targets to Akt.
Despite this, we previously observed that the final effect on AML cell proliferation was very similar
for PI3K, Akt or mTOR inhibition in individual patients, even though the effect varied among patients
and both antiproliferative effects and growth enhancement could be detected [27]. These observations
suggest that despite the complex direct effects of different strategies on intracellular signalling of
the leukemic cells, the final effect on AML cell proliferation is less dependent on which mediator
is targeted.
As outlined in Section 2.4 and Table 1, many different inhibitors are now being developed,
including inhibitors to various single mediators, dual inhibitors and agonists to inhibitory regulators
of the pathway. It is difficult to predict the functional effects of each inhibitor in primary human AML
cells, and possibly the optimal therapeutic approach/agent will differ among patients. Additional
experimental studies as well as careful clinical studies including detailed biological characterization of
the treated patients will be essential to answer these questions.
7.2. The Complexity and Heterogeneity of Human AML; the Consequences from PI3K-Akt-mTOR Inhibition in
the Leukemic Cells with Regard to Communication with Neighbouring Cells May Differ among Patients
AML is a very heterogeneous disease, and, as pointed out above, patients differ with regard
to the effect of PI3K-Akt-mTOR inhibition on AML cell proliferation. However, AML cells differ
considerably with regard to the expression of various cell surface molecules (adhesion molecules,
cytokine receptors) [193,194] as well as the constitutive release profile [195]. Due to these variations
between primary AML cells their communication with leukaemia-supporting neighbouring cells in
the BM microenvironment will also differ, and the direct effects of PI3K-Akt-mTOR inhibition on the
AML cell communications with neighbouring cells will thereby be difficult to predict and may even
increase the patient heterogeneity with regard to the final effect of the treatment on the AML cells.
The importance of targeting the neighbouring leukaemia-supporting microenvironment is clearly
illustrated by the use of new targeted therapies in chronic lymphocytic leukaemia [196,197]. Both the
Bruton tyrosine kinase inhibitor ibrutinib and the PI3K inhibitor idelalisib are now approved for
treatment of this disease, and inhibition of the communication between the leukemic and the
neighbouring stromal cells seems important for their antileukemic efficiency. As described in our
present review and discussed more in detail in a recent article [193] similar mechanisms may be
important in AML. Furthermore, oral administration is possible for both drugs and the toxicity is
acceptable; they may therefore become useful in low-toxicity AML stabilizing treatment in elderly and
unfit patients [197,198].
7.3. The Complex Effects of PI3K-Akt-mTOR Signalling in MSCs
The microenvironment of a tumour resembles that of a chronic wound where MSCs are attracted
by the local release of inflammatory chemokines [65,199], such as chemokines [93], growth factors [50],
and pro-inflammatory IL-6 [93]. The recruited MSCs may then differentiate into tumour-associated
fibroblasts and pericytes [50,65] that support the cancer cells indirectly (e.g., induction of angiogenesis) [65]
or directly through growth factor release [50,158,200]. Pericytes can produce extracellular matrix
components that further support angiogenesis [50,65]. Similar mechanisms may also be operative in
human AML [138]. Furthermore, the fraction of mature osteoblasts relative to immature MSCs seems
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to be substantially higher in AML than normal BM [22] and this may further support [50] and favour
the growth of the leukemic cells over normal hematopoietic cells [201]. Finally, it should be pointed
out that BM MSCs in AML include cells with abnormal karyotype [202], but the clinical importance
of this observation is uncertain because these alterations thus far could not be linked with prognosis.
These abnormal cells can support growth and development of malignant cells [65], but normal MSCs
can also support the proliferation of primary human AML cells (Brenner, Revised Version submitted).
MSCs express a wide range of surface molecules that may be involved in the crosstalk with
neighbouring cells, e.g., AML cells. Even though PI3K-Akt-mTOR is important for the differentiation
of MSCs, very little is known about the effect of this pathway on the expression of single surface
molecules or single soluble mediators. It is therefore difficult to predict based on the current knowledge
how PI3K-Akt-mTOR inhibition will alter the ability of MSCs to communicate and thereby support
AML cells in the BM niches through direct cell-cell contact or through their release of soluble mediators.
7.4. The Complex Effects of PI3K-Akt-mTOR Signalling in Macrophages and the Role of Other
Immunocompetent Cells
PI3K-Akt-mTOR is important for macrophage polarization, and targeting of this pathway may
even increase macrophage release of AML-supporting soluble mediators. Thus, targeting of this
pathway will alter the ability of these cells to communicate with neighbouring AML cells in the
stem cell niches, but due to the patient heterogeneity in AML the consequences of the induced
polarization/inhibition may differ among patients.
Our previous experimental studies have demonstrated that coculture of primary human AML
cells and BM MSCs increase the levels of several cytokines in their common microenvironment,
including the levels of several chemokines that are important for T cell trafficking [135,203].
Even though only the macrophages are important in the formation of the stem cell niches (see above),
other immunocompetent cells may also be important for leukemogenesis or chemosensitivity.
Recent studies of auto-transplanted patients suggest that the antileukemic reactivity of autologous
T cells is important for the effect of intensive chemotherapy in AML [162]. On the other hand, previous
studies suggest that T cells may support leukemogenesis or be important for chemosensitivity in human
AML because activated T cells can release several cytokines that function as growth factors for primary
human AML cells, e.g., G-CSF and IL-3 [204–208]. Thus, it is not known how the various strategies
for inhibition of PI3K-Akt-mTOR will influence the balance between antileukemic and potentially
AML-supporting activity by immunocompetent BM cells (e.g., monocytes/macrophages, T cells).
8. Final Conclusions
Based on the experimental studies reviewed in this article it is likely that the effect of
PI3K-Akt-mTOR inhibition will differ among AML patients. Thus, the optimal design of future
clinical studies will require additional experimental investigations to characterize in detail the direct
and indirect effects of this treatment on the AML cells. Such studies are necessary in order to clarify
which patients are likely to benefit from this treatment, and which pathway mediator is to be targeted
in order to achieve maximal antileukemic effect for each individual patient.
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